Long-Term Safety of Sogroya for Adult Growth Hormone Deficiency Under Investigation

Adult Growth Hormone Deficiency (AGHD) is a chronic condition requiring lifelong treatment, often with daily growth hormone injections. While Sogroya (somapacitan), a long-acting growth hormone, offers a convenient once-weekly dosing regimen, there's a critical need for extensive real-world data on its long-term safety and effectiveness in routine clinical practice. This multi-national observational study aims to address this gap by monitoring patients over an extended period.

As an ongoing, enrolling study, specific results regarding Sogroya's long-term safety and effectiveness are not yet available. However, the study is designed to gather comprehensive real-world data on the safety profile of Sogroya (somapacitan) in adults with AGHD. Researchers will meticulously monitor for adverse events, serious adverse events, and other safety outcomes over the nearly 10-year study period. The primary objective is to investigate the long-term safety of Sogroya in 400 participants under routine clinical practice, providing crucial real-world data on its tolerability. The study will also collect information on the effectiveness of Sogroya in managing AGHD symptoms and improving patient quality of life, as observed in a diverse, multi-national patient population, offering insights into its real-world utility.